Amunix Pharmaceuticals, Inc

Darragh Maccann

Volker Schellenberger

Eric Johansen

Lucas Liu

Philipp Kuhn

Viktoriya Dubrovskaya

Bryan Irving

James Mcclory

Milton To

Andre Frenzel

Angela Henkensiefken

Mika Derynck

The disclosure describes antigen-binding molecules with binding specificity to cluster of differentiationT cell receptor (CD), antigen-binding molecules with binding specificity to prostate-specific membrane antigen (PSMA), cleavable linker sequences, and protease-activatable bispecific fusion proteins such as protease-activatable T cell engagers, as well as uses and methods of treatment.

Compositions targeting prostate-specific membrane antigen and methods for making and using the same

Disclosed herein are polypeptides, and methods of making and using such polypeptides, that comprise a bispecific antibody construct covalently linked to an extended recombinant polypeptide comprising a barcode fragment releasable from said polypeptide upon digestion by a protease, and a Release Segment that can be proteolytically cleaved wherein said cleavage releases the bispecific antibody construct from the extended recombinant polypeptide.

HER-2 targeted bispecific compositions and methods for making and using the same

Growing community of inventors

Magherfelt, United Kingdom

Darragh Maccann